The new Dementia Trials Accelerator is set to receive £20m of government funding The Dementia Trials Accelerator, led by the UK Dementia Research Institute and Health Data Research UK and funded by ...

The World Health Organization’s (WHO) newly published report has placed tuberculosis (TB) as the leading infectious disease killer in 2023, surpassing COVID-19. Newly identified TB cases climbed to ...

Make no mistake, innovation in diabetes care is critical. Diabetes never takes a break. People with diabetes manage their condition on their own, 365 days a year – making multiple therapy decisions ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval of lecanemab. This particular therapy is a monoclonal antibody treatment for use among patient populations with mild ...

Chiesi Group has appointed Laura Vergani as SVP of Global Communications Chiesi Group has announced that Laura Vergani has joined as Senior Vice President of Global Communications & Public Affairs.

The European Commission has approved the subcutaneous (SC) formulation of DARZALEX (daratumumab) in combination with ...

Innovative Trials has appointed Ian Keith as Finance and Business Services Director Innovative Trials has appointed Ian Keith, who has been supporting the company as a Business Consultant since the ...

Primary open-angle glaucoma affects around 2% of adults aged 40 years and older in the UK The National Institute for Health and Care Excellence (NICE) has issued guidance recommending Santen’s ...

The two-year programme will use virtual reality technology to teach essential skills A £4.5m initiative has been launched to address the growing skills shortage in the UK’s medicines manufacturing ...

The London hub is home to life sciences companies including Novartis, Engitix and invoX Pharma Vivan Therapeutics has signed a new five-year lease at White City Place, a biotech hub in London home to ...

There are around 55,100 new prostate cancer cases in the UK every year HBC Immunology (HBCI) has announced that an oral formulation of its lead peptide “significantly augmented” the anti-tumour ...